By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK


Company News
Eisai Inc. (ESALF.PK) Release: Lenvatinib Delays Deterioration In Certain Domains Of Quality Of Life In Patients With Unresectable Hepatocellular Carcinoma As Compared To Sorafenib In Phase III REFLECT Study 9/11/2017 7:26:09 AM
Eisai Inc. (ESALF.PK) Release: Combination Of Lenvatinib And Pembrolizumab Results In Notable Response Rates For Patients With Advanced Renal Cell Carcinoma Based On Interim Analysis Of Ongoing Phase Ib/II Trial 9/11/2017 6:35:11 AM
Dr. Kirk Shepard Appointed Senior Vice President, Global Medical Affairs Of The Oncology Business Group At Eisai Inc. (ESALF.PK) 3/17/2017 10:06:38 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Regulatory Approval Of BELVIQ (Lorcaserin Hcl) In Brazil 12/19/2016 11:57:47 AM
Interim Results From Phase 1b/2 Study Evaluating The Combination Of Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) And Eisai Inc. (ESALF.PK)’s HALAVEN (Eribulin Mesylate) Injection In Metastatic Triple-Negative Breast Cancer Presented At 2016 SABCS 12/12/2016 10:37:21 AM
Rebecca Jolley Appointed Senior Vice President Americas Commercial, Oncology Business Group At Eisai Inc. (ESALF.PK) 12/1/2016 11:56:21 AM
FDA Grants Fast Track Designation For Development Of E2609, Eisai Inc. (ESALF.PK)'s BACE Inhibitor For Early Alzheimer's Disease 11/17/2016 7:45:53 AM
Eisai Inc. (ESALF.PK) Announces Initiation Of Two Phase 3 Clinical Trials With FYCOMPA (Perampanel) 10/28/2016 7:11:44 AM
Eisai Inc. (ESALF.PK)'s LENVIMA (lenvatinib) Nominated For Galien Foundation's Best Pharmaceutical Product 10/27/2016 9:32:44 AM
Eisai Inc. (ESALF.PK), Oklahoma Medical Research Foundation (OMRF) Enter Autoimmune Disease Research Collaboration 10/26/2016 7:07:23 AM